Logo image of GNLX

GENELUX CORP (GNLX) Stock Price, Quote, News and Overview

NASDAQ:GNLX - Nasdaq - US36870H1032 - Common Stock - Currency: USD

2.85  +0.53 (+22.84%)

After market: 2.8 -0.05 (-1.75%)

GNLX Quote, Performance and Key Statistics

GENELUX CORP

NASDAQ:GNLX (5/8/2025, 4:08:23 PM)

After market: 2.8 -0.05 (-1.75%)

2.85

+0.53 (+22.84%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.89
52 Week Low1.6
Market Cap107.53M
Shares37.73M
Float33.07M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08/bmo
IPO01-26 2023-01-26


GNLX short term performance overview.The bars show the price performance of GNLX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20 -30

GNLX long term performance overview.The bars show the price performance of GNLX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GNLX is 2.85 USD. In the past month the price increased by 23.38%. In the past year, price decreased by -25.59%.

GENELUX CORP / GNLX Daily stock chart

GNLX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 328.29B
AMGN AMGEN INC 13.1 146.27B
GILD GILEAD SCIENCES INC 12.68 122.21B
VRTX VERTEX PHARMACEUTICALS INC N/A 110.44B
REGN REGENERON PHARMACEUTICALS 12.36 59.13B
ARGX ARGENX SE - ADR 299.54 34.75B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.61B
ONC BEIGENE LTD-ADR 5.88 25.43B
BNTX BIONTECH SE-ADR N/A 22.78B
NTRA NATERA INC N/A 22.10B
SMMT SUMMIT THERAPEUTICS INC N/A 18.31B
BIIB BIOGEN INC 7.48 17.35B

About GNLX

Company Profile

GNLX logo image Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Company Info

GENELUX CORP

2625 Townsgate Road, Suite 230

Westlake Village CALIFORNIA US

Employees: 24

GNLX Company Website

GNLX Investor Relations

Phone: 18052679889

GENELUX CORP / GNLX FAQ

What is the stock price of GENELUX CORP today?

The current stock price of GNLX is 2.85 USD. The price increased by 22.84% in the last trading session.


What is the ticker symbol for GENELUX CORP stock?

The exchange symbol of GENELUX CORP is GNLX and it is listed on the Nasdaq exchange.


On which exchange is GNLX stock listed?

GNLX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GENELUX CORP stock?

11 analysts have analysed GNLX and the average price target is 18.36 USD. This implies a price increase of 544.21% is expected in the next year compared to the current price of 2.85. Check the GENELUX CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENELUX CORP worth?

GENELUX CORP (GNLX) has a market capitalization of 107.53M USD. This makes GNLX a Micro Cap stock.


How many employees does GENELUX CORP have?

GENELUX CORP (GNLX) currently has 24 employees.


What are the support and resistance levels for GENELUX CORP (GNLX) stock?

GENELUX CORP (GNLX) has a support level at 2.65 and a resistance level at 3.06. Check the full technical report for a detailed analysis of GNLX support and resistance levels.


Is GENELUX CORP (GNLX) expected to grow?

The Revenue of GENELUX CORP (GNLX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the GNLX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENELUX CORP (GNLX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENELUX CORP (GNLX) stock pay dividends?

GNLX does not pay a dividend.


When does GENELUX CORP (GNLX) report earnings?

GENELUX CORP (GNLX) will report earnings on 2025-05-08, before the market open.


What is the Price/Earnings (PE) ratio of GENELUX CORP (GNLX)?

GENELUX CORP (GNLX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.96).


What is the Short Interest ratio of GENELUX CORP (GNLX) stock?

The outstanding short interest for GENELUX CORP (GNLX) is 6.96% of its float. Check the ownership tab for more information on the GNLX short interest.


GNLX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to GNLX. When comparing the yearly performance of all stocks, GNLX is a bad performer in the overall market: 84.88% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GNLX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to GNLX. While GNLX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GNLX Financial Highlights

Over the last trailing twelve months GNLX reported a non-GAAP Earnings per Share(EPS) of -0.96. The EPS increased by 20.66% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -86.04%
ROE -113.68%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-4%
Sales Q2Q%N/A
EPS 1Y (TTM)20.66%
Revenue 1Y (TTM)-95.29%

GNLX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to GNLX. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of -8.11% and a revenue growth -100% for GNLX


Ownership
Inst Owners14.1%
Ins Owners16.37%
Short Float %6.96%
Short Ratio12.54
Analysts
Analysts83.64
Price Target18.36 (544.21%)
EPS Next Y-8.11%
Revenue Next Year-100%